A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease.
Like other amyloid-targeting medications, Leqembi can cause brain swelling or small brain bleeds. In Eisai's study, 13% of drug recipients had swelling and 17% has small brain bleeds.
While the brain swelling and bleeds may cause only minimal symptoms such as dizziness and vision problems, they occasionally can be severe — and several Leqembi users have died while taking the drug, including two who were on blood-thinning medications. Patients also may experience temporary reactions after the infusions that can include fever, flu-like chills, nausea and blood pressure fluctuations.The drug is only intended for people in the very early stages of Alzheimer's who also have that tell-tale amyloid buildup.
As patients gradually worsen, it's not clear how long they should continue getting the twice-a-month IV infusions. Study participants are being tracked for longer periods, and other research is exploring even earlier use — before people with amyloid buildup show symptoms.Eisai says the drug should be available by Jan. 23, but most patients will likely have to wait months to get it.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
New Alzheimer’s Drug Approved by FDA, Promises to Slow DiseaseBreaking: A new Alzheimer's drug has been cleared for use in the U.S. Doctors say it could transform the way the disease is treated.
Weiterlesen »
FDA approves new Alzheimer’s drug that appears to slow progression of diseaseBREAKING: FDA approves Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.
Weiterlesen »
FDA approves new experimental Alzheimer's drugThe Food and Drug Administration granted accelerated approval for Eisai and Biogen's experimental Alzheimer's drug, lecanemab, on Friday, offering a new treatment option for the more than 6.5 million people with Alzheimer's in the United States.
Weiterlesen »
FDA approves new Alzheimer's drug lecanemab that appears to slow the memory-robbing diseaseFederal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.
Weiterlesen »
FDA Approves New Alzheimer's Drug, but There Are Lingering QuestionsLecanemab appeared to slow down cognitive decline in people with early Alzheimer's, though some experts question its real-world benefits.
Weiterlesen »
EXPLAINER: New drug slows Alzheimer's but comes with caveatsA new Alzheimer’s drug is hitting the market with experts voicing a lot of caution
Weiterlesen »